Under FDA clinical hold, Aardvark Therapeutics seeks path forward for metabolic drug

The FDA’s full clinical hold formally suspends all testing of Aardvark Therapeutics’ drug for Prader-Willi syndrome, a rare inherited metabolic disorder that leads to excessive eating. Earlier this year, Aardvark voluntarily suspended all testing of its small molecule after a cardiovascular problem arose in a healthy volunteer.

The post Under FDA Clinical Suspension, Aardvark Therapeutics Seeks Path Forward for Metabolic Drugs appeared first on MedCity News.